Edwards Lifesciences (NYSE:EW) Releases Earnings Results, Beats Expectations By $0.04 EPS

Edwards Lifesciences (NYSE:EW) issued its earnings results on Tuesday. The medical research company reported $0.59 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.55 by $0.04, Zacks reports. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. Edwards Lifesciences updated its FY 2025 guidance to 2.400-2.500 EPS and its Q1 2025 guidance to 0.580-0.640 EPS.

Edwards Lifesciences Stock Up 6.9 %

Shares of NYSE:EW opened at $75.83 on Thursday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. The company has a market cap of $44.72 billion, a PE ratio of 10.94, a price-to-earnings-growth ratio of 3.64 and a beta of 1.10. Edwards Lifesciences has a 52 week low of $58.93 and a 52 week high of $96.12. The firm has a 50 day simple moving average of $72.47 and a 200 day simple moving average of $69.32.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on EW shares. Evercore ISI cut their target price on shares of Edwards Lifesciences from $75.00 to $73.00 and set an “in-line” rating on the stock in a research note on Wednesday. Wolfe Research lowered shares of Edwards Lifesciences from a “peer perform” rating to an “underperform” rating and set a $60.00 price objective on the stock. in a research note on Thursday, January 16th. Robert W. Baird dropped their price objective on shares of Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating on the stock in a research note on Friday, October 25th. Canaccord Genuity Group increased their price objective on shares of Edwards Lifesciences from $63.00 to $68.00 and gave the stock a “hold” rating in a research note on Thursday, December 5th. Finally, Barclays increased their price objective on shares of Edwards Lifesciences from $85.00 to $88.00 and gave the stock an “overweight” rating in a research note on Monday, December 2nd. One investment analyst has rated the stock with a sell rating, fourteen have given a hold rating and twelve have given a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $79.71.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 500 shares of the stock in a transaction that occurred on Thursday, January 16th. The shares were sold at an average price of $68.76, for a total value of $34,380.00. Following the completion of the sale, the vice president now owns 23,189 shares in the company, valued at $1,594,475.64. This represents a 2.11 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 1.29% of the stock is owned by insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.